In contrast, a much more pronounced difference between the metabolic profiles of detemir and glargine was reported by Lucidi et al who found a 42% higher GIRAUC after glargine in a group of overweight (mean BMI 29 kg/m2), insulin-dependent patients with type 2 diabetes [14]. This evidence concerns the gene INS and type 2 diabetes mellitus.